In an Era of ctDNA, Is Metabolomics the New Kid on the Block?

Brian Andrew Van Tine Costas Andreas Lyssiotis

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)

Mass action drives the serum homeostasis of metabolites. Recent developments in biofluid metabolomics suggest the potential to harness these changes using small volumes of blood to diagnose, monitor, and risk stratify patients with cancer. This current study may represent a complementary technology to circulating tumor DNA detection. See related article by Larkin et al., p. 1651.

Keyphrases

circulating tumor
cell free
circulating tumor cells
mass spectrometry
ms ms
risk assessment
label free
real time pcr